Building Confidence Through Enterprise Imaging

Riverain Technologies’ ClearRead Detect augments the standard PA/AP chest X-ray by marking the regions of interest on the ClearRead Bone Suppressed image that warrant a second look by a radiologist. With no additional radiation dose to the patient or changes to existing imaging protocols, radiologists are able to detect more actionable nodules sooner, leading to improved patient outcomes.

ClearRead Detect helps radiologists identify nodules that may be early-stage lung cancer, while offering high sensitivity with minimal false positives.

Key Advantages of ClearRead Detect
- Identifies lung cancer up to 18 months sooner
- Enables detection of 1 in 2 previously missed subtle and very subtle nodules
- Produces a 75% detection sensitivity of hard to find lung nodules with 0.5 false positives per image
- Markers are scaled to reflect the nodule size without obscuring the boundary
- No additional radiation dose or changes to existing imaging protocols are required
- Seamlessly displays CAD results on existing PACS reading workstations
- Easy, one-click access to the CAD results
- FDA approved

Detect lung cancer up to 18 months sooner with the use of ClearRead Detect.

“We could have significantly decreased the time to diagnosis if we had used the ClearRead CAD system. The performance of the software at detecting early, subtle lung cancers was really good and the false positive rate was very low - less than one per image.”

- Dr. Chip Gilkeson, University Hospitals Case Medical Center/Case Western Reserve University
Studies prove that ClearRead Detect aids radiologists in more effectively detecting subtle, actionable nodules. With a false positive rate of 0.5 per image and a 75% sensitivity for the most subtle nodules, ClearRead Detect provides a critical second pair of eyes without additional patient dose or changes to existing imaging protocols. A study presented at RSNA 2013 showed that with the use of ClearRead Detect, radiologists were able to detect lung cancer up to 18 months sooner. 

Early detection of lung cancer is the key to improving patient outcomes, and chest X-rays continue to be a critical modality in the battle against lung cancer. Getting more out of the most common radiological exam based on ClearRead Detect is a simple, cost effective addition to any thoracic program.

Undetected nodules of actionable size create a risk that radiologists or hospitals can’t afford to take. Studies show that ClearRead Detect can find up to 1 in 2 actionable nodules that were previously missed. 

About Riverain
Riverain Technologies™ is a medical software innovator that develops solutions to aid radiologists in the early detection of disease. With the use of Riverain’s ClearRead X-ray Suite and ClearRead CT, radiologists are able to optimize the use of existing equipment. This enables radiologists to better utilize their diagnostic expertise in image interpretation for identification of diseases, such as lung cancer.

References
2. Riverain Medical OnGuard FDA PMA Reader Study Results 2009

*Requires ClearRead Bone Suppress™